 |
|
|
| |
Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of Nitazoxanide with Peginterferon Alfa-2a and
Ribavirin in Nonresponders (NR) with Chronic HCV Genotype 1: Week 28 Interim Analysis
|
| |
| |
44th EASL April 23-26, 2009 Copenhagen
Reported by Jules Levin
M.L. Shiffman,1 A. Ahmed,2 I.M. Jacobson,3 R.E. Pruitt,4 E.B. Keeffe,2,5 and STEALTH C-2 Investigators.
1Virginia Commonwealth University Medical Center, Richmond, VA, USA 2Stanford University Medical Center, Stanford, CA, USA 3Weill Cornell Medical
College, New York, NY, USA, 4Nashville GI Specialists, Nashville, TN, USA and 5Romark Institute for Medical Research, Tampa, FL, USA
|
| |
|
|
|
|
|
